New combo therapy shows promise for Hard-to-Treat colorectal cancer

NCT ID NCT07512674

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new treatment approach for people with advanced colorectal cancer that has spread to the liver, lungs, or abdomen and cannot be removed with surgery. The treatment combines a short course of radiation with immunotherapy (tislelizumab), chemotherapy (CAPOX), and a targeted drug (bevacizumab). The goal is to see if this combination can shrink tumors and control the disease. The study involves 33 participants and is currently active but no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH INITIALLY UNRESECTABLE MSS-TYPE ADVANCED COLORECTAL CANCER WITH LIVER AND/OR LUNG AND PERITONEAL METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China